{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T23:42:45Z","timestamp":1777765365972,"version":"3.51.4"},"reference-count":22,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chronic graft-versus-host disease (cGVHD) remains a major hurdle to the success of hematopoietic stem cell transplantation, directly affecting patient morbidity and mortality. Impaired regulatory T-cell (Treg) recovery in patients with cGVHD has led to clinical studies aiming to increase peripheral Treg numbers. We conducted phase 1 dose-escalation clinical trials testing the feasibility and safety of using freshly isolated donor-derived Treg infusions in steroid-refractory\/dependent cGVHD. The phase 1 was extended to a preliminary phase 2 trial, resulting in a total of 33 treated patients. We report that Treg purification from donor leukapheresis using CliniMACS were feasible and that Treg infusions were safe. Importantly, Treg infusions resulted in improved symptoms, particularly at higher Treg doses. Global responses were observed in 71% of patients, and 52% of patients had at least a 2-point improvement in the cGVHD severity scale. Furthermore, improvement in cGVHD symptoms resulted in reductions in corticosteroids, ruxolitinib, and mycophenolate in 58%, 83%, and 33% of patients, respectively, whereas calcineurin inhibitors were discontinued in 75% of patients. Exploratory analyses revealed the detection of infused Treg clonotypes up to 12 months after infusion and suggest increased Treg numbers in circulation. We observed increases in serum levels of interleukin-7 and interferon gamma and decreases in soluble CD13 and suppression of tumorigenicity 2 over time, which were not statistically significant after adjustment for multiple comparisons. Although these studies were not powered to assess efficacy, they suggest potential therapeutic benefits of donor-derived Treg in cGVHD treatment and highlight the need for larger phase 2 clinical trials. The trials were registered at www.clinicaltrials.gov as #NCT02385019 and #NCT03683498.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017996","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T20:22:25Z","timestamp":1770236545000},"page":"2904-2915","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Phase 1\/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6492-2931","authenticated-orcid":false,"given":"Maria V. D.","family":"Soares","sequence":"first","affiliation":[{"name":"1Jo\u00e3o Lacerda Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal"},{"name":"2Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0639-574X","authenticated-orcid":false,"given":"Virginia Escamilla","family":"G\u00f3mez","sequence":"additional","affiliation":[{"name":"3Instituto de Biomedicina de Sevilla, Instituto de Biomedicina de Sevilha (Universidad de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Junta de Andaluc\u00eda, Consejo Superior de Investigaciones Cient\u00edficas), Seville, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-1481","authenticated-orcid":false,"given":"Rita I.","family":"Azevedo","sequence":"additional","affiliation":[{"name":"1Jo\u00e3o Lacerda Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0930-0902","authenticated-orcid":false,"given":"Paulo N. G.","family":"Pereira","sequence":"additional","affiliation":[{"name":"1Jo\u00e3o Lacerda Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7487-3793","authenticated-orcid":false,"given":"Teresa Caballero","family":"Vel\u00e1zquez","sequence":"additional","affiliation":[{"name":"3Instituto de Biomedicina de Sevilla, Instituto de Biomedicina de Sevilha (Universidad de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Junta de Andaluc\u00eda, Consejo Superior de Investigaciones Cient\u00edficas), Seville, Spain"}]},{"given":"Laura","family":"Mendes","sequence":"additional","affiliation":[{"name":"4Servi\u00e7o de Imuno-Hemoterapia, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8803-3453","authenticated-orcid":false,"given":"Ana C.","family":"Alho","sequence":"additional","affiliation":[{"name":"1Jo\u00e3o Lacerda Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal"},{"name":"2Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"},{"name":"5Servi\u00e7o de Hematologia e Transplanta\u00e7\u00e3o de Medula, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-9860","authenticated-orcid":false,"given":"Estefan\u00eda","family":"Garc\u00eda-Guerrero","sequence":"additional","affiliation":[{"name":"3Instituto de Biomedicina de Sevilla, Instituto de Biomedicina de Sevilha (Universidad de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Junta de Andaluc\u00eda, Consejo Superior de Investigaciones Cient\u00edficas), Seville, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3415-5284","authenticated-orcid":false,"given":"Clara B.","family":"Garcia-Calder\u00f3n","sequence":"additional","affiliation":[{"name":"3Instituto de Biomedicina de Sevilla, Instituto de Biomedicina de Sevilha (Universidad de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Junta de Andaluc\u00eda, Consejo Superior de Investigaciones Cient\u00edficas), Seville, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8255-9822","authenticated-orcid":false,"given":"Kukatharmini","family":"Tharmaratnam","sequence":"additional","affiliation":[{"name":"6Department of Health Data Science, University of Liverpool, Institute of Population Health, Liverpool, United Kingdom"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3236-7435","authenticated-orcid":false,"given":"In\u00eas A.","family":"Cabral","sequence":"additional","affiliation":[{"name":"1Jo\u00e3o Lacerda Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3264-4156","authenticated-orcid":false,"given":"Ana C.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"1Jo\u00e3o Lacerda Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal"}]},{"given":"Clara","family":"Juncal","sequence":"additional","affiliation":[{"name":"4Servi\u00e7o de Imuno-Hemoterapia, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1605-6573","authenticated-orcid":false,"given":"Susana","family":"Roncon","sequence":"additional","affiliation":[{"name":"7Servi\u00e7o de Terapia Celular, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, Porto, Portugal"}]},{"given":"Ana Teresa","family":"Pais","sequence":"additional","affiliation":[{"name":"1Jo\u00e3o Lacerda Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal"}]},{"given":"Alfonso Rodriguez","family":"Gil","sequence":"additional","affiliation":[{"name":"3Instituto de Biomedicina de Sevilla, Instituto de Biomedicina de Sevilha (Universidad de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Junta de Andaluc\u00eda, Consejo Superior de Investigaciones Cient\u00edficas), Seville, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5713-3440","authenticated-orcid":false,"given":"Eduardo","family":"Espada","sequence":"additional","affiliation":[{"name":"1Jo\u00e3o Lacerda Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal"},{"name":"2Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"},{"name":"5Servi\u00e7o de Hematologia e Transplanta\u00e7\u00e3o de Medula, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9981-030X","authenticated-orcid":false,"given":"Anabela","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"4Servi\u00e7o de Imuno-Hemoterapia, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1170-7808","authenticated-orcid":false,"given":"Ana","family":"Gar\u00e7\u00e3o","sequence":"additional","affiliation":[{"name":"4Servi\u00e7o de Imuno-Hemoterapia, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"given":"Marie-Laure","family":"Yaspo","sequence":"additional","affiliation":[{"name":"8Max Planck Institute for Molecular Genetics, Berlin, Germany"}]},{"given":"Hans-J\u00f6rg","family":"Warnatz","sequence":"additional","affiliation":[{"name":"8Max Planck Institute for Molecular Genetics, Berlin, Germany"}]},{"given":"Hans","family":"Lehrach","sequence":"additional","affiliation":[{"name":"8Max Planck Institute for Molecular Genetics, Berlin, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-3320","authenticated-orcid":false,"given":"Laura","family":"Ward","sequence":"additional","affiliation":[{"name":"1Jo\u00e3o Lacerda Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-0538","authenticated-orcid":false,"given":"Nuno L.","family":"Barbosa-Morais","sequence":"additional","affiliation":[{"name":"9Nuno Morais Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal"}]},{"given":"Ana Miguel","family":"Quintas","sequence":"additional","affiliation":[{"name":"10Servi\u00e7o de Oftalmologia, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"given":"Paulo","family":"Palmela","sequence":"additional","affiliation":[{"name":"11Servi\u00e7o de Estomatologia, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"given":"Cec\u00edlia","family":"Caldas","sequence":"additional","affiliation":[{"name":"11Servi\u00e7o de Estomatologia, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"given":"Rosa","family":"Ferreira","sequence":"additional","affiliation":[{"name":"12Servi\u00e7o de Transplanta\u00e7\u00e3o de Medula \u00d3ssea, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, Porto, Portugal"}]},{"given":"Lu\u00eds","family":"Leite","sequence":"additional","affiliation":[{"name":"12Servi\u00e7o de Transplanta\u00e7\u00e3o de Medula \u00d3ssea, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, Porto, Portugal"}]},{"given":"Carlos","family":"Martins","sequence":"additional","affiliation":[{"name":"5Servi\u00e7o de Hematologia e Transplanta\u00e7\u00e3o de Medula, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"given":"Fernanda","family":"Louren\u00e7o","sequence":"additional","affiliation":[{"name":"5Servi\u00e7o de Hematologia e Transplanta\u00e7\u00e3o de Medula, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"given":"Ra\u00fal","family":"Moreno","sequence":"additional","affiliation":[{"name":"5Servi\u00e7o de Hematologia e Transplanta\u00e7\u00e3o de Medula, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]},{"given":"Fernando","family":"Campilho","sequence":"additional","affiliation":[{"name":"12Servi\u00e7o de Transplanta\u00e7\u00e3o de Medula \u00d3ssea, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, Porto, Portugal"}]},{"given":"Christopher Paul","family":"Cheyne","sequence":"additional","affiliation":[{"name":"6Department of Health Data Science, University of Liverpool, Institute of Population Health, Liverpool, United Kingdom"}]},{"given":"Marta","family":"Garcia-Fi\u00f1ana","sequence":"additional","affiliation":[{"name":"6Department of Health Data Science, University of Liverpool, Institute of Population Health, Liverpool, United Kingdom"}]},{"given":"Ant\u00f3nio","family":"Campos","sequence":"additional","affiliation":[{"name":"12Servi\u00e7o de Transplanta\u00e7\u00e3o de Medula \u00d3ssea, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, Porto, Portugal"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Baron","sequence":"additional","affiliation":[{"name":"13Division of Hematology, Department of Medicine, Centre Hospitalier Universitaire of Li\u00e8ge, Li\u00e8ge, Belgium"}]},{"given":"Mario","family":"Arpinati","sequence":"additional","affiliation":[{"name":"14Unit of Cellular Therapy and Hematopoietic Stem Cell Transplantation, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3541-6196","authenticated-orcid":false,"given":"Petra","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"15Leibniz Institute for Immunotherapy, Regensburg, Germany"}]},{"given":"Matthias","family":"Edinger","sequence":"additional","affiliation":[{"name":"15Leibniz Institute for Immunotherapy, Regensburg, Germany"},{"name":"16Department of Internal Medicine III (Hematology and Oncology), University Hospital Regensburg, Regensburg, Germany"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[{"name":"17Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-4669","authenticated-orcid":false,"given":"Jerome","family":"Ritz","sequence":"additional","affiliation":[{"name":"17Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA"}]},{"given":"Carlos Pinho","family":"Vaz","sequence":"additional","affiliation":[{"name":"12Servi\u00e7o de Transplanta\u00e7\u00e3o de Medula \u00d3ssea, Instituto Portugu\u00eas de Oncologia do Porto Francisco Gentil, Porto, Portugal"}]},{"given":"Jos\u00e9 A.","family":"Perez-Simon","sequence":"additional","affiliation":[{"name":"3Instituto de Biomedicina de Sevilla, Instituto de Biomedicina de Sevilha (Universidad de Sevilla, Hospital Universitario Virgen del Roc\u00edo, Junta de Andaluc\u00eda, Consejo Superior de Investigaciones Cient\u00edficas), Seville, Spain"},{"name":"18Department of Hematology, University Hospital Virgen del Rocio, Seville, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1351-2809","authenticated-orcid":false,"given":"Jo\u00e3o F.","family":"Lacerda","sequence":"additional","affiliation":[{"name":"1Jo\u00e3o Lacerda Lab, Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal"},{"name":"2Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal"},{"name":"5Servi\u00e7o de Hematologia e Transplanta\u00e7\u00e3o de Medula, Hospital de Santa Maria, Unidade Local de Sa\u00fade Santa Maria, Lisbon, Portugal"}]}],"member":"234","reference":[{"issue":"20","key":"2026042911220104800_bib1","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"issue":"26","key":"2026042911220104800_bib2","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2026042911220104800_bib3","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","article-title":"FDA approval summary: ruxolitinib for treatment of steroid-refractory acute graft-versus-host disease","volume":"25","author":"Przepiorka","year":"2020","journal-title":"Oncologist"},{"issue":"4","key":"2026042911220104800_bib4","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.17835","article-title":"The clinical landscape of chronic graft-versus-host disease management in 2021","volume":"196","author":"Holtzman","year":"2022","journal-title":"Br J Haematol"},{"key":"2026042911220104800_bib5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"2026042911220104800_bib6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2006-02-003996","article-title":"High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT","volume":"108","author":"Rezvani","year":"2006","journal-title":"Blood"},{"issue":"5","key":"2026042911220104800_bib7","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI41072","article-title":"Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation","volume":"120","author":"Matsuoka","year":"2010","journal-title":"J Clin Invest"},{"issue":"8","key":"2026042911220104800_bib8","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"issue":"5","key":"2026042911220104800_bib9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2015-10-672345","article-title":"Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD","volume":"127","author":"Alho","year":"2016","journal-title":"Blood"},{"issue":"MAR","key":"2026042911220104800_bib10","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fimmu.2019.00334","article-title":"I and stem cell memory T cell subset recovery reveals opposing reconstitution patterns in CD4 and CD8 T cells in chronic graft vs. host disease","volume":"10","author":"Soares","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"2026042911220104800_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2026042911220104800_bib12","doi-asserted-by":"crossref","first-page":"389.e1-401.e1","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2026042911220104800_bib13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"14","key":"2026042911220104800_bib14","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2026042911220104800_bib15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse","volume":"124","author":"Martelli","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2026042911220104800_bib16","doi-asserted-by":"crossref","first-page":"e127244","DOI":"10.1172\/jci.insight.127244","article-title":"Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients","volume":"4","author":"Meyer","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"2026042911220104800_bib17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.clim.2009.06.001","article-title":"First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells","volume":"133","author":"Trzonkowski","year":"2009","journal-title":"Clin Immunol"},{"issue":"6","key":"2026042911220104800_bib18","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.ymthe.2022.02.025","article-title":"Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD","volume":"30","author":"Landwehr-Kenzel","year":"2022","journal-title":"Mol Ther"},{"key":"2026042911220104800_bib19","doi-asserted-by":"crossref","first-page":"1081644","DOI":"10.3389\/fcell.2022.1081644","article-title":"Clinical adoptive regulatory T Cell therapy: state of the art, challenges, and prospective","volume":"10","author":"Amini","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"21","key":"2026042911220104800_bib20","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1182\/bloodadvances.2021006625","article-title":"A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease","volume":"6","author":"Whangbo","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2026042911220104800_bib21","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1182\/bloodadvances.2020003739","article-title":"Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia","volume":"5","author":"Pierini","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2026042911220104800_bib22","doi-asserted-by":"crossref","first-page":"8348","DOI":"10.1038\/s41598-022-12407-x","article-title":"Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib","volume":"12","author":"Rodr\u00edguez-Gil","year":"2022","journal-title":"Sci Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2904\/2515788\/blooda_adv-2025-017996-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/2904\/2515788\/blooda_adv-2025-017996-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:22:10Z","timestamp":1777476130000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/2904\/566426\/Phase-1-2-trials-of-donor-regulatory-T-cells-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017996","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,5,12]]}}}